ROCEPHIN

Compare ROCEPHIN  to:
Compare
Compare

Generic Name for ROCEPHIN

Ceftriaxone sodium 250mg, 500mg, 1g, 2g; IM or IV inj; sodium content 3.6mEq/g.

Legal Classification:

Rx

Pharmacological Class for ROCEPHIN

Cephalosporin.

Manufacturer of ROCEPHIN

Roche Laboratories

Indications for ROCEPHIN

Susceptible bacterial septicemia, acute bacterial otitis media, lower respiratory tract, UTIs, skin and skin structure, bone and joint, pelvic inflammatory disease (PID), intraabdominal infections, meningitis, uncomplicated gonorrhea. Surgical prophylaxis.

Adult dose for ROCEPHIN

1–2g IM or IV once daily or in 2 equally divided doses; max 4g/day. Gonorrhea: 250mg IM once. Surgery: 1g IV ½–2 hours pre-op.

Children's dosing for ROCEPHIN

50–75mg/kg per day in equally divided doses every 12 hours; max 2g/day. Skin and skin structures: may give as a single dose or in 2 equally divided doses every 12 hours; max 2g/day. Meningitis: 100mg/kg (max 4g) for 1 dose, then 100mg/kg per day (max 4g/day) once daily or in 2 equally divided doses every 12 hours for 7–14 days. Otitis media: 50mg/kg (max 1g) IM once.

Contraindications for ROCEPHIN

Hyperbilirubinemic neonates (esp. prematures). Concomitant calcium-containing solutions or products in newborns.

Warnings/Precautions for ROCEPHIN

Penicillin or other allergy. Discontinue if gallbladder sonographic abnormalities, symptoms or disease occur. Renal failure: monitor; decrease dose if drug accumulation occurs. Chronic hepatic disease or malnutrition (impaired Vit. K synthesis or storage), monitor prothrombin time. Both renal and hepatic impairment: usual max 2g/day. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for ROCEPHIN

See Contraindications. Potentiated by probenecid.

Adverse Reactions for ROCEPHIN

Inj site reactions, hematologic effects (eg, eosinophilia), rash, diarrhea, elevated liver enzymes; rare: allergic pneumonitis, seizures, anaphylaxis.

How is ROCEPHIN supplied?

Vials (250mg, 500mg, 1g)—1, 10
Vials (2g)—10

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions